thalidomide and Lymphoma, T Cell, Peripheral
thalidomide has been researched along with Lymphoma, T Cell, Peripheral in 14 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
" Of 13 assessable patients (nine with adult T-cell leukaemia-lymphoma, four with other peripheral T-cell lymphomas) receiving lenalidomide, dose-limiting toxic effects were reported in three patients during cycle 1 (one grade 4 thrombocytopenia [cohort 2], one grade 3 QT prolongation on electrocardiogram [cohort 3], and one grade 3 fatigue and grade 4 thrombocytopenia [cohort 3])." | 9.22 | Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study. ( Aoki, T; Asou, N; Chen, N; Choi, I; Imaizumi, Y; Maruyama, D; Midorikawa, S; Nosaka, K; Ogura, M; Ohtsu, T; Taguchi, J; Tobinai, K; Tsukasaki, K; Uchida, T; Uike, N; Utsunomiya, A, 2016) |
" Of 13 assessable patients (nine with adult T-cell leukaemia-lymphoma, four with other peripheral T-cell lymphomas) receiving lenalidomide, dose-limiting toxic effects were reported in three patients during cycle 1 (one grade 4 thrombocytopenia [cohort 2], one grade 3 QT prolongation on electrocardiogram [cohort 3], and one grade 3 fatigue and grade 4 thrombocytopenia [cohort 3])." | 5.22 | Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study. ( Aoki, T; Asou, N; Chen, N; Choi, I; Imaizumi, Y; Maruyama, D; Midorikawa, S; Nosaka, K; Ogura, M; Ohtsu, T; Taguchi, J; Tobinai, K; Tsukasaki, K; Uchida, T; Uike, N; Utsunomiya, A, 2016) |
" Haemocytopenia was the predominant adverse effect, and acute toxicity was moderate, tolerable and well managed in both arms." | 2.84 | The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers. ( Chang, Y; Duan, W; Fu, X; Li, L; Li, X; Li, Z; Nan, F; Sun, Z; Wang, X; Wu, J; Yan, J; Young, KH; Zhang, L; Zhang, M; Zhang, X, 2017) |
" In conclusion, the poor results obtained with lenalidomide in combination with vorinostat and dexamethasone provide no arguments that could justify further investigation of this drug combination for the treatment of relapsed PTCL." | 2.79 | Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial. ( Egle, A; Greil, R; Hopfinger, G; Lang, A; Linkesch, W; Melchardt, T; Nösslinger, T; Weiss, L, 2014) |
"Patients received oral lenalidomide 25mg once daily on days 1-21 of each 28-day cycle for a maximum of 24 months, until disease progression or development of unacceptable adverse events (AEs)." | 2.78 | A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. ( Bosly, A; Coiffier, B; Delarue, R; Fitoussi, O; Gabarre, J; Glaisner, S; Haioun, C; Li, J; Lister, J; Morschhauser, F; Quach, H; Thieblemont, C, 2013) |
"We report the cases of 3 patients with hematological malignancies and complex karyotypes involving der(5; 17) (p10;q10), which results in the loss of 5q and 17p." | 2.50 | der(5;17)(p10;q10) is a recurrent but rare whole-arm translocation in patients with hematological neoplasms: a report of three cases. ( Aoyama, Y; Furukawa, Y; Harada, N; Kumura, T; Manabe, M; Mugitani, A; Ohta, T; Okita, J; Tarakuwa, T, 2014) |
"Lenalidomide treatment demonstrated for the first time in the literature impressive and long-term clinical efficacy in a heavily pretreated chemorefractory AITL patient." | 1.39 | Impressive activity of lenalidomide monotherapy in refractory angioimmunoblastic T-cell lymphoma: report of a case with long-term follow-up. ( Bocchia, M; Cencini, E; Defina, M; Fabbri, A; Fontanelli, G; Gozzetti, A; Mazzei, MA; Pietrini, A; Volterrani, L, 2013) |
Research
Studies (14)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (14.29) | 29.6817 |
2010's | 11 (78.57) | 24.3611 |
2020's | 1 (7.14) | 2.80 |
Authors
Authors | Studies |
---|---|
Wang, Y | 1 |
Zhang, M | 2 |
Song, W | 1 |
Cai, Q | 1 |
Zhang, L | 2 |
Sun, X | 1 |
Zou, L | 1 |
Zhang, H | 1 |
Wang, L | 1 |
Xue, H | 1 |
Li, L | 1 |
Duan, W | 1 |
Li, X | 1 |
Fu, X | 1 |
Wang, X | 1 |
Wu, J | 1 |
Sun, Z | 1 |
Zhang, X | 1 |
Chang, Y | 1 |
Nan, F | 1 |
Yan, J | 1 |
Li, Z | 1 |
Young, KH | 1 |
Morschhauser, F | 2 |
Fitoussi, O | 1 |
Haioun, C | 1 |
Thieblemont, C | 1 |
Quach, H | 1 |
Delarue, R | 1 |
Glaisner, S | 1 |
Gabarre, J | 1 |
Bosly, A | 1 |
Lister, J | 1 |
Li, J | 1 |
Coiffier, B | 2 |
Hopfinger, G | 1 |
Nösslinger, T | 1 |
Lang, A | 1 |
Linkesch, W | 1 |
Melchardt, T | 1 |
Weiss, L | 1 |
Egle, A | 1 |
Greil, R | 1 |
Manabe, M | 1 |
Okita, J | 1 |
Tarakuwa, T | 1 |
Harada, N | 1 |
Aoyama, Y | 1 |
Kumura, T | 1 |
Ohta, T | 1 |
Furukawa, Y | 1 |
Mugitani, A | 1 |
Federico, M | 1 |
Caballero, D | 1 |
Dearden, C | 1 |
Jäger, U | 1 |
Trümper, L | 1 |
Zucca, E | 1 |
Gomes da Silva, M | 1 |
Pettengell, R | 1 |
Weidmann, E | 1 |
d'Amore, F | 1 |
Tilly, H | 1 |
Zinzani, PL | 2 |
Toumishey, E | 1 |
Prasad, A | 1 |
Dueck, G | 1 |
Chua, N | 1 |
Finch, D | 1 |
Johnston, J | 1 |
van der Jagt, R | 1 |
Stewart, D | 1 |
White, D | 1 |
Belch, A | 1 |
Reiman, T | 1 |
Ogura, M | 1 |
Imaizumi, Y | 1 |
Uike, N | 1 |
Asou, N | 1 |
Utsunomiya, A | 1 |
Uchida, T | 1 |
Aoki, T | 1 |
Tsukasaki, K | 1 |
Taguchi, J | 1 |
Choi, I | 1 |
Maruyama, D | 1 |
Nosaka, K | 1 |
Chen, N | 1 |
Midorikawa, S | 1 |
Ohtsu, T | 1 |
Tobinai, K | 1 |
Gottardi, M | 1 |
Danesin, C | 1 |
Canal, F | 1 |
Dei Tos, AP | 1 |
Stefani, PM | 1 |
Calistri, E | 1 |
Salvadori, U | 1 |
Gherlinzoni, F | 1 |
O'Connor, OA | 1 |
Qin, Y | 1 |
Shi, YK | 1 |
He, XH | 1 |
Yang, JL | 1 |
Zhang, CG | 1 |
Zhou, SY | 1 |
Liu, XF | 1 |
Liu, P | 1 |
Yang, S | 1 |
Zhou, LQ | 1 |
Han, XH | 1 |
Yao, JR | 1 |
Pellegrini, C | 1 |
Broccoli, A | 1 |
Stefoni, V | 1 |
Gandolfi, L | 1 |
Quirini, F | 1 |
Argnani, L | 1 |
Berti, E | 1 |
Derenzini, E | 1 |
Pileri, S | 1 |
Baccarani, M | 1 |
Fabbri, A | 1 |
Cencini, E | 1 |
Pietrini, A | 1 |
Gozzetti, A | 1 |
Defina, M | 1 |
Fontanelli, G | 1 |
Mazzei, MA | 1 |
Volterrani, L | 1 |
Bocchia, M | 1 |
Ramasamy, K | 1 |
Lim, Z | 1 |
Pagliuca, A | 1 |
Salisbury, JR | 1 |
Mufti, GJ | 1 |
Devereux, S | 1 |
Clinical Trials (8)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Chidamide With PET Regimen for Angioimmunoblastic T Cell Lymphoma, a Multicentric, Single Arm, Open Label Phase II Clinical Trial[NCT03273452] | Phase 2 | 30 participants (Anticipated) | Interventional | 2017-03-01 | Recruiting | ||
A Randomized Controlled Multi-center Clinical Trial on Treatment of Peripheral T-cell Lymphoma With DGPT Regiment (Gemcitabine,Cisplatin,Prednisone ,Thalidomide )[NCT01664975] | Phase 4 | 100 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
A Phase II, Prospective, Single-center Study of Lenalidomide in Combination With CHOP in Patients With Untreated PTCL[NCT04423926] | Phase 1/Phase 2 | 91 participants (Anticipated) | Interventional | 2020-06-10 | Recruiting | ||
A Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid®) in Subjects With Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma[NCT00655668] | Phase 2 | 54 participants (Actual) | Interventional | 2008-03-01 | Terminated (stopped due to Decision not to pursue as single agent in the study population.) | ||
Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.[NCT03964480] | 1,000 participants (Anticipated) | Observational [Patient Registry] | 2018-10-14 | Recruiting | |||
A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma[NCT00322985] | Phase 2 | 40 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphoma[NCT01169298] | Phase 1 | 13 participants (Actual) | Interventional | 2010-07-01 | Completed | ||
[NCT01036399] | Phase 2 | 9 participants (Actual) | Interventional | 2008-11-30 | Terminated (stopped due to The EC withdrawn the approval becuase of possible conflicts of interests between our Institute and Supporter (Celgene)) | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Progression-free Survival
(NCT01664975)
Timeframe: up to end of follow-up-phase (approximately 24 months)
Intervention | participants (Number) |
---|---|
GDPT Regimen | 35 |
CHOP Regimen | 27 |
Duration of Response
Kaplan-Meier Estimate of duration of response calculated as the time from first computed tomography (CT) Scan or magnetic resonance imaging (MRI) that demonstrates at least a partial response to the first documentation of disease progression, including death due to Non-Hodgkin's Lymphoma. (NCT00655668)
Timeframe: Up to 24 months
Intervention | Months (Median) |
---|---|
Single Agent Lenalidomide | 3.55 |
Progression-Free Survival
Kaplan-Meier estimate of progression-free survival is defined as the start of study drug therapy to the first observation of disease progression or death due to any cause. (NCT00655668)
Timeframe: Up to 24 months
Intervention | Months (Median) |
---|---|
Single Agent Lenalidomide | 2.53 |
Participants Categorized by Best Response as Determined by Investigator
"Participant response assessed by investigator; criteria by B. Cheson in Journal of Clinical Oncology, 1999 (see article for more detail):~Complete Response(CR): Complete disappearance of all detectable disease~Complete Response Unconfirmed(CRu): CR, but indeterminate bone marrow~Partial Response(PR): >50% decrease in six largest nodes/nodal masses~Stable Disease(SD): Less than PR, but not progressive disease~Relapsed Disease: In CR/CRu Patients, new lesions seen or increased by >=50% in previous sites~Progressive Disease(PD): >=50% increase from low in PR/Non-Responders" (NCT00655668)
Timeframe: Up to 24 months
Intervention | Participants (Number) | |||||||
---|---|---|---|---|---|---|---|---|
Complete Response (CR) | Complete Response Unconfirmed (CRu) | Partial Response (PR) | Stable Disease (SD) | Progressive Disease (PD) | No Response Assessment | Other | Tumor Control (CR+CRu+PR+SD) | |
Single Agent Lenalidomide | 4 | 2 | 6 | 16 | 16 | 9 | 1 | 28 |
Safety
Summary of Treatment-Emergent Events in Safety Population (participants with at least one dose of study drug). Events assessed using National Cancer Institute, Common Terminology Criteria for Adverse Events (NCI CTCAE, Version 3: Following is the scale: Grade 1=Mild Adverse Event (AE), Grade 2=Moderate AE, Grade 3=Severe and Undesirable AE, Grade 4=Life-threatening or Disabling AE, and Grade 5=Death Related to AE.) (NCT00655668)
Timeframe: Up to 24 months
Intervention | Participants (Number) | |||||||
---|---|---|---|---|---|---|---|---|
At least 1 adverse event (AE) | At least 1 AE related to drug | At least 1 NCI CTCAE Grade 3-4 AE | At least 1 NCI CTCAE Gr 3-4 AE related to drug | At least 1 serious adverse event (SAE) | At least 1 SAE related to drug | At least 1 AE leading to drug withdrawal (WD) | At least 1 AE leading to drug interruption/WD | |
Single Agent Lenalidomide | 53 | 40 | 34 | 19 | 29 | 16 | 21 | 19 |
Reviews
3 reviews available for thalidomide and Lymphoma, T Cell, Peripheral
Article | Year |
---|---|
der(5;17)(p10;q10) is a recurrent but rare whole-arm translocation in patients with hematological neoplasms: a report of three cases.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Aneuploidy; Antineoplastic Combi | 2014 |
Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemo | 2014 |
Novel agents in development for peripheral T-cell lymphoma.
Topics: Aminopterin; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2010 |
Trials
7 trials available for thalidomide and Lymphoma, T Cell, Peripheral
Other Studies
4 other studies available for thalidomide and Lymphoma, T Cell, Peripheral
Article | Year |
---|---|
Complete remission induced by thalidomide in a case of angioimmunoblastic T-cell lymphoma refractory to autologous stem cell transplantation.
Topics: Hematopoietic Stem Cell Transplantation; Humans; Immunoblastic Lymphadenopathy; Lymphoma, T-Cell, Pe | 2008 |
[Clinical features and prognostic factors of angioimmunoblastic T cell lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxo | 2010 |
Impressive activity of lenalidomide monotherapy in refractory angioimmunoblastic T-cell lymphoma: report of a case with long-term follow-up.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; C | 2013 |
Successful treatment of refractory angioimmunoblastic T-cell lymphoma with thalidomide and dexamethasone.
Topics: Adult; Angiogenesis Inhibitors; Dexamethasone; Drug Therapy, Combination; Humans; Lymphoma, T-Cell, | 2006 |